Market News AIOpen the app

DSGN stock news · Design Therapeutics

Stories about Design Therapeutics (DSGN) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for DSGN

Follow Design Therapeutics (DSGN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for DSGN
Free on the App Store and Google Play, or on the web.
  1. Nov 5, 2026, 5:34 PM ET · Opinion

    RBC Capital Markets lowered its price target for Design Therapeutics from $20 to $19.

    Neutral

    RBC cut Design Therapeutics' target by 5%, from $20 to $19, but kept its Outperform rating and favorable pipeline view. The mixed update does not clearly change DSGN's outlook.